GEMOGENOVATUCEL-T
Ewing Sarcoma
Gradalis, Inc.Cell therapyPhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
57 Active assets in the Ewing Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Milton S. Hershey Medical Center | Phase 3 | BB |
Nivolumab Children's National Research Institute | Phase 2 | B |
Cyclophosphamide Essen Biotech | Phase 2 | B |
Nadravaleucel Brenda Cooper, MD | Phase 2 | B |
NOGITECAN Pfizer | Phase 2 | B |
View all 50 →
Same molecule, other indications
GEMOGENOVATUCEL-T is also rated in:
Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant
B
Indicative · Phase 3
56 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →